A detailed history of Sandy Spring Bank transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Sandy Spring Bank holds 63 shares of REGN stock, worth $51,942. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63
Previous 66 4.55%
Holding current value
$51,942
Previous $69,000 4.35%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 25, 2024

SELL
$1024.09 - $1201.76 $3,072 - $3,605
-3 Reduced 4.55%
63 $66,000
Q2 2024

Aug 06, 2024

SELL
$883.2 - $1071.19 $27,379 - $33,206
-31 Reduced 31.96%
66 $69,000
Q1 2024

May 08, 2024

BUY
$902.69 - $993.35 $29,788 - $32,780
33 Added 51.56%
97 $93,000
Q4 2023

Jan 26, 2024

SELL
$775.18 - $881.7 $136,431 - $155,179
-176 Reduced 73.33%
64 $56,000
Q2 2023

Aug 04, 2023

BUY
$700.03 - $830.35 $700 - $830
1 Added 0.42%
240 $172,000
Q4 2022

Feb 10, 2023

BUY
$705.89 - $766.39 $122,118 - $132,585
173 Added 262.12%
239 $172,000
Q3 2022

Nov 02, 2022

BUY
$573.97 - $724.32 $1,147 - $1,448
2 Added 3.13%
66 $45,000
Q2 2022

Jul 21, 2022

BUY
$548.35 - $738.84 $1,096 - $1,477
2 Added 3.23%
64 $37,000
Q2 2021

Aug 09, 2021

BUY
$472.8 - $558.54 $23,640 - $27,927
50 Added 416.67%
62 $34,000
Q1 2021

May 03, 2021

SELL
$446.73 - $548.2 $1,786 - $2,192
-4 Reduced 25.0%
12 $5,000
Q2 2020

Aug 12, 2020

BUY
$493.32 - $643.92 $1,973 - $2,575
4 Added 33.33%
16 $9,000
Q1 2020

May 01, 2020

BUY
$336.18 - $494.43 $4,034 - $5,933
12 New
12 $6,000
Q2 2018

Aug 03, 2018

SELL
$284.6 - $344.99 $9,107 - $11,039
-32 Closed
0 $0
Q1 2018

May 04, 2018

SELL
$315.82 - $393.78 $31,582 - $39,378
-100 Reduced 75.76%
32 $11,000
Q4 2017

Feb 02, 2018

BUY
$358.63 - $469.95 $11,476 - $15,038
32 Added 32.0%
132 $50,000
Q2 2017

Aug 11, 2017

BUY
N/A
100
100 $49,000

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $88.4B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track Sandy Spring Bank Portfolio

Follow Sandy Spring Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sandy Spring Bank, based on Form 13F filings with the SEC.

News

Stay updated on Sandy Spring Bank with notifications on news.